Research ArticleArticle
Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans
Mehul Dave, Mike Nash, Graeme C. Young, Harma Ellens, Mindy H. Magee, Andrew D. Roberts, Maxine A. Taylor, Robert W. Greenhill and Gary W. Boyle
Drug Metabolism and Disposition March 2014, 42 (3) 415-430; DOI: https://doi.org/10.1124/dmd.113.054486
Mehul Dave
Department of Drug Metabolism and Pharmacokinetics (M.D., M.N., G.C.Y., A.D.R., M.A.T., G.W.B.) and Department of Safety Assessment (R.W.G.), GlaxoSmithKline Research & Development, Ware, United Kingdom, and Department of Drug Metabolism and Pharmacokinetics (H.E.) and Clinical Pharmacology, Modeling and Simulation (M.H.M.), GlaxoSmithKline Research & Development, Upper Merion, Philadelphia
Mike Nash
Department of Drug Metabolism and Pharmacokinetics (M.D., M.N., G.C.Y., A.D.R., M.A.T., G.W.B.) and Department of Safety Assessment (R.W.G.), GlaxoSmithKline Research & Development, Ware, United Kingdom, and Department of Drug Metabolism and Pharmacokinetics (H.E.) and Clinical Pharmacology, Modeling and Simulation (M.H.M.), GlaxoSmithKline Research & Development, Upper Merion, Philadelphia
Graeme C. Young
Department of Drug Metabolism and Pharmacokinetics (M.D., M.N., G.C.Y., A.D.R., M.A.T., G.W.B.) and Department of Safety Assessment (R.W.G.), GlaxoSmithKline Research & Development, Ware, United Kingdom, and Department of Drug Metabolism and Pharmacokinetics (H.E.) and Clinical Pharmacology, Modeling and Simulation (M.H.M.), GlaxoSmithKline Research & Development, Upper Merion, Philadelphia
Harma Ellens
Department of Drug Metabolism and Pharmacokinetics (M.D., M.N., G.C.Y., A.D.R., M.A.T., G.W.B.) and Department of Safety Assessment (R.W.G.), GlaxoSmithKline Research & Development, Ware, United Kingdom, and Department of Drug Metabolism and Pharmacokinetics (H.E.) and Clinical Pharmacology, Modeling and Simulation (M.H.M.), GlaxoSmithKline Research & Development, Upper Merion, Philadelphia
Mindy H. Magee
Department of Drug Metabolism and Pharmacokinetics (M.D., M.N., G.C.Y., A.D.R., M.A.T., G.W.B.) and Department of Safety Assessment (R.W.G.), GlaxoSmithKline Research & Development, Ware, United Kingdom, and Department of Drug Metabolism and Pharmacokinetics (H.E.) and Clinical Pharmacology, Modeling and Simulation (M.H.M.), GlaxoSmithKline Research & Development, Upper Merion, Philadelphia
Andrew D. Roberts
Department of Drug Metabolism and Pharmacokinetics (M.D., M.N., G.C.Y., A.D.R., M.A.T., G.W.B.) and Department of Safety Assessment (R.W.G.), GlaxoSmithKline Research & Development, Ware, United Kingdom, and Department of Drug Metabolism and Pharmacokinetics (H.E.) and Clinical Pharmacology, Modeling and Simulation (M.H.M.), GlaxoSmithKline Research & Development, Upper Merion, Philadelphia
Maxine A. Taylor
Department of Drug Metabolism and Pharmacokinetics (M.D., M.N., G.C.Y., A.D.R., M.A.T., G.W.B.) and Department of Safety Assessment (R.W.G.), GlaxoSmithKline Research & Development, Ware, United Kingdom, and Department of Drug Metabolism and Pharmacokinetics (H.E.) and Clinical Pharmacology, Modeling and Simulation (M.H.M.), GlaxoSmithKline Research & Development, Upper Merion, Philadelphia
Robert W. Greenhill
Department of Drug Metabolism and Pharmacokinetics (M.D., M.N., G.C.Y., A.D.R., M.A.T., G.W.B.) and Department of Safety Assessment (R.W.G.), GlaxoSmithKline Research & Development, Ware, United Kingdom, and Department of Drug Metabolism and Pharmacokinetics (H.E.) and Clinical Pharmacology, Modeling and Simulation (M.H.M.), GlaxoSmithKline Research & Development, Upper Merion, Philadelphia
Gary W. Boyle
Department of Drug Metabolism and Pharmacokinetics (M.D., M.N., G.C.Y., A.D.R., M.A.T., G.W.B.) and Department of Safety Assessment (R.W.G.), GlaxoSmithKline Research & Development, Ware, United Kingdom, and Department of Drug Metabolism and Pharmacokinetics (H.E.) and Clinical Pharmacology, Modeling and Simulation (M.H.M.), GlaxoSmithKline Research & Development, Upper Merion, Philadelphia
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Disposition and Metabolism of Darapladib in Humans
Mehul Dave, Mike Nash, Graeme C. Young, Harma Ellens, Mindy H. Magee, Andrew D. Roberts, Maxine A. Taylor, Robert W. Greenhill and Gary W. Boyle
Drug Metabolism and Disposition March 1, 2014, 42 (3) 415-430; DOI: https://doi.org/10.1124/dmd.113.054486
Research ArticleArticle
Disposition and Metabolism of Darapladib in Humans
Mehul Dave, Mike Nash, Graeme C. Young, Harma Ellens, Mindy H. Magee, Andrew D. Roberts, Maxine A. Taylor, Robert W. Greenhill and Gary W. Boyle
Drug Metabolism and Disposition March 1, 2014, 42 (3) 415-430; DOI: https://doi.org/10.1124/dmd.113.054486
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement